{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T09:32:19Z","timestamp":1792575139879,"version":"4.5.0"},"reference-count":28,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Swedish Foundation for Strategic Research","award":["SM21-0042"],"award-info":[{"award-number":["SM21-0042"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,9,30]]},"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Indications with poor T-cell infiltration or deficiencies in T-cell priming and associated unresponsiveness to established immunotherapies represent an unmet medical need in oncology. CD40-targeting therapies designed to enhance antigen presentation, generate new tumor-specific T cells, and activate tumor-infiltrating myeloid cells to remodel the tumor microenvironment, represent a promising opportunity to meet this need. In this study, we present the first in vivo data supporting a role for tumor-associated antigen (TAA)-mediated uptake and cross-presentation of tumor antigens to enhance tumor-specific T-cell priming using CD40\u00d7TAA bispecific antibodies, a concept we named Neo-X-Prime.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Bispecific antibodies targeting CD40 and either of two cell-surface expressed TAA, carcinoembryonic antigen-related cell adhesion molecule 5 (CEA) or epithelial cell adhesion molecule (EpCAM), were developed in a tetravalent format. TAA-conditional CD40 agonism, activation of tumor-infiltrating immune cells, antitumor efficacy and the role of delivery of tumor-derived material such as extracellular vesicles, tumor debris and exosomes by the CD40\u00d7TAA bispecific antibodies were demonstrated in vitro using primary human and murine cells and in vivo using human CD40 transgenic mice with different tumor models.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The results showed that the CD40\u00d7TAA bispecific antibodies induced TAA-conditional CD40 activation both in vitro and in vivo. Further, it was demonstrated in vitro that they induced clustering of tumor debris and CD40-expressing cells in a dose-dependent manner and superior T-cell priming when added to dendritic cells (DC), ovalbumin (OVA)-specific T cells and OVA-containing tumor debris or exosomes. The antitumor activity of the Neo-X-Prime bispecific antibodies was demonstrated to be significantly superior to the monospecific CD40 antibody, and the resulting T-cell dependent antitumor immunity was directed to tumor antigens other than the TAA used for targeting (EpCAM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The data presented herein support the hypothesis that CD40\u00d7TAA bispecific antibodies can engage tumor-derived vesicles containing tumor neoantigens to myeloid cells such as DCs resulting in an improved DC-mediated cross-priming of tumor-specific CD8<jats:sup>+<\/jats:sup> T cells. Thus, this principle may offer therapeutics strategies to enhance tumor-specific T-cell immunity and associated clinical benefit in indications characterized by poor T-cell infiltration or deficiencies in T-cell priming.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005018","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T04:20:12Z","timestamp":1667362812000},"page":"e005018","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":31,"title":["Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies"],"prefix":"10.1136","volume":"10","author":[{"given":"Karin","family":"H\u00e4gerbrand","sequence":"first","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Varas","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan","family":"Deronic","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barnabas","family":"Nyesiga","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Sundstedt","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lill","family":"Ljung","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Sakellariou","sequence":"additional","affiliation":[{"name":"Department of Immunotechnology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Werchau","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Thagesson","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-5263","authenticated-orcid":false,"given":"David","family":"Gomez Jimenez","sequence":"additional","affiliation":[{"name":"Department of Immunotechnology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lennart","family":"Greiff","sequence":"additional","affiliation":[{"name":"Department of ORL, Head & Neck Surgery, Sk\u00e5ne University Hospital, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Celander","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Smedenfors","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ros\u00e9n","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"B\u00f6l\u00fckbas","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrika","family":"Carlsson","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Levin","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"S\u00e4ll","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"von Schantz","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malin","family":"Lindstedt","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"},{"name":"Department of Immunotechnology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6687-1250","authenticated-orcid":false,"given":"Peter","family":"Ellmark","sequence":"additional","affiliation":[{"name":"Alligator Bioscience AB, Medicon Village, Lund, Sweden"},{"name":"Department of Immunotechnology, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"2025100315212484000_10.11.e005018.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"2025100315212484000_10.11.e005018.2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coi.2021.02.001","article-title":"Resistance mechanisms to checkpoint inhibitors","volume":"69","author":"Weiss","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"2025100315212484000_10.11.e005018.3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","article-title":"Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists","volume":"17","author":"Beatty","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"2025100315212484000_10.11.e005018.4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","article-title":"CD40 agonist antibodies in cancer immunotherapy","volume":"71","author":"Vonderheide","year":"2020","journal-title":"Annu Rev Med"},{"key":"2025100315212484000_10.11.e005018.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164206"},{"key":"2025100315212484000_10.11.e005018.6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0510"},{"key":"2025100315212484000_10.11.e005018.7","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.4.1263"},{"key":"2025100315212484000_10.11.e005018.8","doi-asserted-by":"crossref","first-page":"d1","DOI":"10.2741\/A170","article-title":"Immune regulation by CD40-CD40-L interactions","volume":"2","author":"van Kooten","year":"1997","journal-title":"Front Biosci"},{"key":"2025100315212484000_10.11.e005018.9","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1014-6"},{"key":"2025100315212484000_10.11.e005018.10","doi-asserted-by":"publisher","DOI":"10.1038\/30996"},{"key":"2025100315212484000_10.11.e005018.11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ebiom.2016.01.029","article-title":"Functional Specialty of CD40 and Dendritic Cell Surface Lectins for Exogenous Antigen Presentation to CD8(+) and CD4(+) T Cells","volume":"5","author":"Yin","year":"2016","journal-title":"EBioMedicine"},{"key":"2025100315212484000_10.11.e005018.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0913"},{"key":"2025100315212484000_10.11.e005018.13","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1918971117"},{"key":"2025100315212484000_10.11.e005018.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.05.058"},{"key":"2025100315212484000_10.11.e005018.15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.082107699"},{"key":"2025100315212484000_10.11.e005018.16","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1080\/14712598.2021.1934446","article-title":"Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy","volume":"21","author":"Enell Smith","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"2025100315212484000_10.11.e005018.17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1468956"},{"key":"2025100315212484000_10.11.e005018.18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4001"},{"key":"2025100315212484000_10.11.e005018.19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0493"},{"key":"2025100315212484000_10.11.e005018.20","first-page":"A785","article-title":"751\u2005Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb","volume":"9","author":"Hagerbrand","year":"2021","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"2025100315212484000_10.11.e005018.21","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0128"},{"key":"2025100315212484000_10.11.e005018.22","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3283624305"},{"key":"2025100315212484000_10.11.e005018.23","doi-asserted-by":"publisher","DOI":"10.1016\/0161-5890(92)90156-R"},{"key":"2025100315212484000_10.11.e005018.24","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003264"},{"key":"2025100315212484000_10.11.e005018.25","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1158\/2326-6066.CIR-21-0553","article-title":"A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression","volume":"10","author":"Rigamonti","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"2025100315212484000_10.11.e005018.26","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0805"},{"key":"2025100315212484000_10.11.e005018.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1696"},{"key":"2025100315212484000_10.11.e005018.28","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0575-3"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:21:33Z","timestamp":1759530093000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11,2]]},"published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1136\/jitc-2022-005018"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005018","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11]]}}}